Clinical trials: Epigenetics
Pancreatic Cancer
Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with CC-486 (oral azacitidine) as…
- Trial name
- NCT01845805
- Testing
- oral azacitidine, Observation
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Epithelial Ovarian Cancer
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
The purpose of the study is to determine the optimal dose of CC-486 (oral azacitidine) in combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer (EOC).
- Trial name
- NCT02900560
- Testing
- CC-486, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Translational Research in Oncology
Healthy
National Survey to Understand Ethical, Legal and Social Issues in Communicating to the Public About Epigenetics
Few people realize that environmental pollution and some behaviors like physical activity and tobacco smoking can affect their health by "turning on" or "turning off" certain genes through a process called "epigenetic…
- Trial name
- NCT07020234
- Testing
- Epigenetics Video, Nanotechnology Video
- Where
- United States
- Volunteers
- 2,040 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated…
- Trial name
- NCT02546986
- Testing
- CC-486, Pembrolizumab
- Where
- 33 sites in United States, France and 4 more
- Volunteers
- 100 people
- Sponsor
- Celgene
Breast Neoplasms
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
The purpose of this study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women with estrogen receptor positive (ER+), human…
- Trial name
- NCT02374099
- Testing
- CC-486, Fulvestrant
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 97 people
- Sponsor
- Celgene
Adenosquamous Carcinoma of the Pancreas
Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Background: Pancreatic cancer is one of the most lethal types of cancer. American Society for Clinical Pathology (ASCP) is a highly aggressive type of pancreatic cancer. It is very rare.
- Trial name
- NCT04896073
- Testing
- Minnelide, ECG, CT/MRI
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infection
Functional Interval Training for Veterans Exercising Through Telehealth.
Most Veterans living with HIV are 50 years of age or older and can expect to live more than 20 years longer with HIV medication.
- Trial name
- FIT-VET (NCT04103593)
- Testing
- exercise training
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- VA Office of Research and Development
Non-Small Cell Lung Cancer, Epigenetic Therapy
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
Response Rate
- Trial name
- NA_00084192 (NCT01928576)
- Testing
- Azacitidine, Entinostat, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 143 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mitochondrial Diseases
Mitochondrial Stress, Brain Imaging, and Epigenetics
The MiSBIE study collects biological, behavioral, psychosocial, neuropsychological, and brain imaging data in participants with either: normal mitochondrial function, individuals with the m.3243A>G mitochondrial DNA (mtDNA)…
- Trial name
- MiSBIE (NCT04831424)
- Testing
- Trier social stress test
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Columbia University
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery
This study combines the deoxyribonucleic acid (DNA) methyltransferase inhibitor, 5-azacitidine (5-AZA), with an orally bioavailable histone deacetylase inhibitor, entinostat (SNDX-275), for the adjuvant treatment of patients with…
- Trial name
- NCT01207726
- Testing
- Azacitidine, Entinostat, Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Infant Development, Stress
Multisensory Early Oral Administration of Human Milk in Preterm Infants
The aims of this pilot are to determine the feasibility and acceptability of the Multisensory early oral administration of human milk (M-MILK) intervention, recruitment, retention, and obtain data for sample size estimation.
- Trial name
- M-MILK (NCT06230848)
- Testing
- Multisensory Early Oral Administration of Human Milk (M-MILK)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Loyola University
Major Depressive Disorder, Suicidal Ideation
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation
The study aims to use a combined clinical and translational approach to identify an efficient pharmacotherapy for the acute management of suicidality and the epigenetic regulation associated with the treatment.The primary…
- Trial name
- AFSP (NCT01134731)
- Testing
- paliperidone, lithium
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Alabama at Birmingham
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab…
- Trial name
- abound2L+ (NCT02250326)
- Testing
- nab-paclitaxel IV, CC-486, Duravalumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 240 people
- Sponsor
- Celgene
Breast Cancer, Breast Tumors
Re-expression of ER in Triple Negative Breast Cancers
Patients are being asked to take part in this study because they have metastatic breast cancer that is triple negative (does not express estrogen receptor (ER), progesterone receptor (PR) or HER2).
- Conditions
- Breast Cancer, Breast Tumors, Breast Neoplasms
- Trial name
- NCT01194908
- Testing
- Decitabine, LBH589, Tamoxifen
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Acute Myelogenous Leukemia
Epigenetic Reprogramming in Relapse/Refractory AML
This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
- Trial name
- NCT03263936
- Testing
- Decitabine, Vorinostat, Filgrastim (G-CSF)
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 37 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Follicular Lymphoma, Marginal Zone Lymphoma
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
The purpose of this study is to evaluate the response and safety in subjects receiving the drugs lenalidomide and azacitidine when each drug is given by itself and when the drugs are taken together.
- Trial name
- NCT01121757
- Testing
- azacitidine, lenalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Aging, Epigenetics
Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock
Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.
- Conditions
- Aging, Epigenetics, Inflammatory Mediators
- Trial name
- Topical-RAPA (NCT04608448)
- Testing
- Rapamycin Topical Ointment
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Head and Neck Neoplasms, Lung Neoplasms
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Background: Two experimental drugs, FdCyd (also called 5-fluoro-2'-deoxcytidine), and THU (also called tetrahydrouridine), are undergoing trials to test their effectiveness in treating cancer that has not responded to standard…
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT00978250
- Testing
- 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Major Depressive Disorder
Epigenetic Regulation of BDNF in Major Depression
The investigators will (1) detect the associations between brain-derived neurotrophic factor (BDNF) DNA methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in major depressive…
- Trial name
- NCT01182103
- Where
- Taiwan
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Mild Cognitive Impairment, Metabolic Syndrome
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts…
- Trial name
- NCT03319173
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.